SCHEMBL1870229

SCHEMBL1870229

Cc1ccc(S(=O)(=O)N(C)C(COC(=O)NC(C)(C)C)CC2(O)CCCCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
AGER Q15109 1/20 0.35
GAA P10253 1/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
NPSR1 Q6W5P4 2/20 0.32
ITGB1 P05556 1/20 0.32
ITGA4 P13612 1/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1868241 0.85 AGER (0.39) ALDH1A1HPGDAGERGAANPSR1
SCHEMBL1870231 0.81 ALDH1A1 (0.35) ALDH1A1HPGDAGERHTTNPSR1
SCHEMBL12670096 0.74 AGER (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1863476 0.65 MMP13 (0.38) ALDH1A1HTTMEN1KMT2APLAU
SCHEMBL27829347 0.65 CA9 (0.43) ALDH1A1GAAHTTTP53KMT2A
SCHEMBL1862267 0.65 MMP13 (0.39) ALDH1A1HPGDHTTMEN1KMT2A
SCHEMBL12631978 0.64 CA2 (0.41) ALDH1A1HTTALOX15PLAUPOLB
SCHEMBL28861927 0.62 NPC1 (0.51) ALDH1A1HPGDMAPK1L3MBTL1MEN1
SCHEMBL1863963 0.62 HSD17B10 (0.35) ALDH1A1HPGDGAALMNAHTT
SCHEMBL1864898 0.61 CA2 (0.43) ALDH1A1HTTKMT2APLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE PSEN1 155/4885PSEN2 362/4885APH1B 257/4885
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE PSEN1 155/4885PSEN2 362/4885APH1B 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.